Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 14/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.34 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.34 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17410833 | 0.91 | GHSR (0.43) | GHSRHTTL3MBTL1NPC1RAB9A | |
| SCHEMBL17410883 | 0.91 | GHSR (0.43) | GHSRHTTL3MBTL1NPC1RAB9A | |
| SCHEMBL17410769 | 0.89 | PAX8 (0.35) | GHSRNPC1RAB9AATMMEN1 | |
| SCHEMBL19542375 | 0.88 | FASN (0.40) | MEN1KMT2APRKAG1PRKAA1PRKAB1 | |
| SCHEMBL17411105 | 0.85 | GHSR (0.43) | GHSRHTTL3MBTL1MEN1KMT2A | |
| SCHEMBL17410837 | 0.85 | GHSR (0.43) | GHSRHTTL3MBTL1MEN1KMT2A | |
| SCHEMBL17411014 | 0.84 | FASN (0.39) | L3MBTL1NPC1RAB9AATMMEN1 | |
| SCHEMBL17410393 | 0.81 | FASN (0.38) | GHSRMEN1KMT2APRKAG1PRKAA1 | |
| SCHEMBL17410915 | 0.81 | NAMPT (0.38) | MEN1KMT2APRKAG1PRKAA1PRKAB1 | |
| SCHEMBL17410817 | 0.80 | FASN (0.43) | GHSRHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2021-07-15 | — | — | US | disclosed |
| US-10472342-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10450286-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-10399951-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190241532-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| US-20170312273-A1 | METHODS OF USING FASN INHIBITORS | FORMA THERAPEUTICS, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20160002188-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399951-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | GHSR 4674/4885HTT 1262/4885L3MBTL1 3093/4885 |
| US-20170312273-A1 | METHODS OF USING FASN INHIBITORS | FASN, IL1RN, CCR1 | GHSR 2350/4885HTT 2504/4885L3MBTL1 1703/4885 |
| US-10472342-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | GHSR 4552/4885HTT 708/4885L3MBTL1 3269/4885 |
| US-10450286-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | GHSR 4552/4885HTT 708/4885L3MBTL1 3269/4885 |
| US-20160002188-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | GHSR 4652/4885HTT 1063/4885L3MBTL1 2751/4885 |
| US-20190241532-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | GHSR 4652/4885HTT 1063/4885L3MBTL1 2751/4885 |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | GHSR 4652/4885HTT 1063/4885L3MBTL1 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.